Novartis’ Fabhalta® (iptacopan) reduces proteinuria by 38.3% in IgA Nephropathy Patients
Novartis recently shared promising findings from the Phase III APPLAUSE-IgAN study of Fabhalta® (iptacopan), a Factor B inhibitor targeting the alternative complement pathway, in patients with IgA nephropathy (IgAN). In…
Unveiling the Growing Impact of Chronic Kidney Disease on Patients, the Environment, and Economies
A recent modeling analysis conducted by AstraZeneca, named IMPACT CKD, projects that by 2032, up to 16.5% of the population across eight countries will be afflicted by chronic kidney disease…
Modalis Announces Partnership with Ginkgo Bioworks
Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883) announced that it has entered into an agreement with Ginkgo Bioworks (Ginkgo) to join the Ginkgo Technology Network. This strategic alliance will enable…
Agenus Reveals Latest Phase 1 Findings and Advances in BOT/BAL Development for Metastatic MSS Colorectal Cancer
Agenus Inc. (NASDAQ: AGEN), a renowned player in the realm of discovering and advancing novel immunological treatments for diverse cancers, has disclosed the latest outcomes from its Phase 1 clinical…
Revance Unveils Latest DAXXIFY® Findings at the 2024 American Academy of Neurology Annual Conference
Revance Therapeutics, Inc. (NASDAQ: RVNC) has unveiled significant insights into DAXXIFY® for the treatment of cervical dystonia at the American Academy of Neurology (AAN) annual meeting, running from April 13-18,…
Dermal Fillers Market 2023-2035: Hyaluronic Acid Innovation Drives Expansion – ResearchAndMarkets.com
Introducing the latest addition to ResearchAndMarkets.com’s offerings, the report on the “Global Dermal Fillers Market, 2023-2035”. Estimated at $3 billion in 2023, the global dermal fillers market is poised for…
Comparison Study Shows TheracosBio’s BRENZAVVY® Matches Dapagliflozin in Effectiveness for Chinese Patients with Type 2 Diabetes
TheracosBio has recently published a study titled “Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: a 24-week,…
FDA Approves Ipsen’s Onivyde® as Promising First-Line Treatment for Metastatic Pancreatic Adenocarcinoma
Ipsen (Euronext: IPN; ADR: IPSEY) has announced the approval by the U.S. Food and Drug Administration (FDA) of the supplemental new drug application for Onivyde® (irinotecan liposome injection) in combination…
Ana Petry Utilizes Professional Expertise to Navigate Life After Personal Tragedy
For Ana, this work held profound significance long before she realized she would eventually benefit from it herself. In October 2022, tragedy struck when her older brother, a successful entrepreneur…
U.S. FDA Conducts Inspection of Lupin’s Dabhasa Facility, Finds No Observations
Lupin Limited, a leading global pharmaceutical company, announced today that the United States Food and Drug Administration (U.S. FDA) has successfully completed a Good Manufacturing Practice (GMP) Inspection of its…
Strengthening Global Health and Well-Being: Collaborative Efforts between WHO and the Netherlands
The Hague, April 10, 2024—In a significant milestone for their enduring partnership, the World Health Organization (WHO) and the Netherlands convened to discuss shared priorities and the alignment of strategic…
Nigeria Leads Globally with Introduction of Revolutionary 5-in-1 Meningitis Vaccine
In a groundbreaking development, Nigeria has emerged as the global pioneer in introducing a new vaccine, known as Men5CV, endorsed by the World Health Organization (WHO). This innovative vaccine provides…